Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

NCT02038816 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped accrual too slow, insufficient patients

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Deferasirox + Azacitidine
DRUG: Azacitidine

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]